Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 17;31(11):1505-1517.
doi: 10.1097/QAD.0000000000001521.

Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV

Deborah J Anderson  1 , Joseph A Politch, Larry Zeitlin, Andy Hiatt, Kadryn Kadasia, Kenneth H Mayer, Ruth M Ruprecht, Francois Villinger, Kevin J Whaley
Affiliations
Review

Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV

Deborah J Anderson et al. AIDS. .

Abstract

: Passive immunization, the transfer of antibodies to a nonimmune individual to provide immunological protection, has been used for over 100 years to prevent and treat human infectious diseases. The introduction of techniques to produce human mAbs has revolutionized the field, and a large number of human mAbs have been licensed for the treatment of cancer, autoimmune and inflammatory diseases. With the recent discovery and production of highly potent broadly neutralizing and other multifunctional antibodies to HIV, mAbs are now being considered for HIV therapy and prophylaxis. In this review, we briefly present recent advances in the anti-HIV mAb field and outline strategies for the selection, engineering and production of human mAbs, including the modification of their structure for optimized stability and function. We also describe results from nonhuman primate studies and phase 1 clinical trials that have tested the safety, tolerability, pharmacokinetics, and efficacy of mAb-based HIV prevention strategies, and discuss the future of parenteral and topical mAb administration for the prevention of HIV transmission.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Figures

Figure 1
Figure 1. HIV broadly neutralizing monoclonal antibodies and their binding sites
From: Sievers, Schaarf, West, Bjorkman; Curr Opin HIV AIDS 2015.
Figure 2
Figure 2
Fc Receptor-Mediated Antibody Dependent Functions that Boost the Immune Response to HIV and HIV-infected Cells
Figure 3
Figure 3. Manufacturing Estimates for mAb Drug Substance
TEM = Techno-economic models
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. von Behring E, Kitasato S. Uber das zustandekommen der diptherie-immunitat und der tetanus-immunitat bei thieren. Deutsche Medizinische Wochenschrift. 1890;16:1113–1114. - PubMed
    1. Hey A. History and Practice: Antibodies in Infectious Diseases. Microbiol Spectr. 2015;3 AID-0026-2014. - PubMed
    1. Cohn EJ. The history of plasma fractionation. In: Andrus EC, editor. Advances in Military Medicine. Boston: Little, Brown and Co; 1948.
    1. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602–614. - PMC - PubMed
    1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. - PubMed

Publication types

MeSH terms